MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ
10.69
+1.20
+12.64%
Closed 19:58 06/17 EDT
OPEN
9.55
PREV CLOSE
9.49
HIGH
10.85
LOW
9.39
VOLUME
233.70K
TURNOVER
0
52 WEEK HIGH
10.85
52 WEEK LOW
2.310
MARKET CAP
57.17M
P/E (TTM)
-6.2580
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LPCN last week (0610-0614)?
Weekly Report · 1d ago
Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024
Phase 2 results on LPCN 1148 in cirrhosis featured in oral presentation at the European Association for the Study of Liver (EASL) Congress in Milan, Italy. The presentation is featured in the symposium "Revolutionary Advances in Liver Disease Research"
Benzinga · 06/10 12:02
Weekly Report: what happened at LPCN last week (0603-0607)?
Weekly Report · 06/10 09:35
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
NASDAQ · 06/06 12:50
Lipocine Sets Employee Bonuses and Expands Stock Plan
TipRanks · 06/03 21:52
Weekly Report: what happened at LPCN last week (0527-0531)?
Weekly Report · 06/03 09:36
Weekly Report: what happened at LPCN last week (0520-0524)?
Weekly Report · 05/27 09:37
Here's Why Momentum in Lipocine (LPCN) Should Keep going
NASDAQ · 05/21 12:50
More
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Webull offers Lipocine Inc stock information, including NASDAQ: LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.